Carregant...
Combination Therapy for Inhibitor Reversal in Haemophilia A Using Monoclonal Anti-CD20 and Rapamycin
Development of antibodies (inhibitors) against coagulation factor VIII (FVIII) is a major complication of intravenous replacement therapy in haemophilia A (HA). Current immune tolerance induction (ITI) regimens are not universally effective. Rituximab, a B cell-depleting antibody against CD20, has s...
Guardat en:
| Publicat a: | Thromb Haemost |
|---|---|
| Autors principals: | , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5222884/ https://ncbi.nlm.nih.gov/pubmed/27683758 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1160/TH16-05-0404 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|